Eupraxia Pharmaceuticals Management
Management criteria checks 3/4
Eupraxia Pharmaceuticals' CEO is James Helliwell, appointed in Jul 2012, has a tenure of 13.5 years. total yearly compensation is $1.38M, comprised of 28.5% salary and 71.5% bonuses, including company stock and options. directly owns 1.73% of the company’s shares, worth $7.93M. The average tenure of the management team and the board of directors is 3.2 years and 3.3 years respectively.
Key information
James Helliwell
Chief executive officer
US$1.4m
Total compensation
| CEO salary percentage | 28.49% |
| CEO tenure | 13.5yrs |
| CEO ownership | 1.7% |
| Management average tenure | 3.2yrs |
| Board average tenure | 3.3yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | -US$32m |
| Jun 30 2025 | n/a | n/a | -US$31m |
| Mar 31 2025 | n/a | n/a | -US$27m |
| Dec 31 2024 | US$1m | US$394k | -US$26m |
| Sep 30 2024 | n/a | n/a | -US$28m |
| Jun 30 2024 | n/a | n/a | -US$27m |
| Mar 31 2024 | n/a | n/a | -US$30m |
| Dec 31 2023 | US$517k | US$363k | -US$28m |
| Sep 30 2023 | n/a | n/a | -US$26m |
| Jun 30 2023 | n/a | n/a | -US$24m |
| Mar 31 2023 | n/a | n/a | -US$20m |
| Dec 31 2022 | US$953k | US$325k | -US$18m |
| Sep 30 2022 | n/a | n/a | -US$14m |
| Jun 30 2022 | n/a | n/a | -US$14m |
| Mar 31 2022 | n/a | n/a | -US$14m |
| Dec 31 2021 | US$1m | US$297k | -US$19m |
Compensation vs Market: James's total compensation ($USD1.38M) is below average for companies of similar size in the US market ($USD2.28M).
Compensation vs Earnings: James's compensation has increased whilst the company is unprofitable.
CEO
James Helliwell (51 yo)
Dr. James A. Helliwell, M.D., FRCPC serves as the Chief Executive Officer since July 2012 at Eupraxia Pharmaceuticals Inc. and served as its President until May 3, 2021. Dr. Helliwell serves as a Clinical...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 13.5yrs | US$1.38m | 1.73% $ 7.9m | |
| Chief Scientific Officer & COO | 13.3yrs | US$776.95k | 0.091% $ 420.1k | |
| Chief Business Officer | 3.2yrs | US$445.82k | 0.086% $ 394.4k | |
| Chief Medical Officer | 2.7yrs | US$718.01k | 0.016% $ 72.5k | |
| Chief Financial Officer | less than a year | US$2.04m | 1.6% $ 7.3m | |
| Executive VP | no data | no data | no data |
Experienced Management: EPRX's management team is considered experienced (3.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 13.5yrs | US$1.38m | 1.73% $ 7.9m | |
| Independent Chairman | 13yrs | US$127.25k | 0.072% $ 332.5k | |
| Independent Director | 4.8yrs | US$115.06k | 0.037% $ 171.0k | |
| Independent Director | 13yrs | US$108.85k | 0.67% $ 3.1m | |
| Independent Director | 1.3yrs | US$193.91k | 4.1% $ 18.8m | |
| Independent Director | 13yrs | US$115.06k | 2.55% $ 11.7m | |
| Independent Director | 13yrs | US$108.85k | 0.45% $ 2.1m | |
| Chairman of Clinical Advisory Board | 1.7yrs | no data | no data | |
| Member of Clinical Advisory Board | 1.7yrs | no data | no data | |
| Member of Clinical Advisory Board | 1.7yrs | no data | no data | |
| Member of Clinical Advisory Board | 1.7yrs | no data | no data | |
| Member of Clinical Advisory Board | 1.7yrs | no data | no data |
Experienced Board: EPRX's board of directors are considered experienced (3.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/22 19:06 |
| End of Day Share Price | 2026/01/22 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Eupraxia Pharmaceuticals Inc. is covered by 7 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tania Armstrong-Whitworth | Canaccord Genuity |
| Kristen Kluska | Cantor Fitzgerald & Co. |
| Gum-Ming Lowe | Craig-Hallum Capital Group LLC |